The Medical Letter on Drugs and Therapeutics
Lenacapavir (Sunlenca) for Multidrug-Resistant HIV
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Lenacapavir (Sunlenca) for Multidrug-Resistant HIV
The FDA has approved oral and injectable formulations of the HIV-1 capsid inhibitor lenacapavir (Sunlenca – Gilead) for use with other antiretroviral drugs to treat multidrug-resistant HIV-1 infection (MDR-HIV) in heavily treatment-experienced...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Lenacapavir (Sunlenca) for Multidrug-Resistant HIV
Article code: 1675c
 Electronic, downloadable article - $45

Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.